Bach Pharma, Inc. has assembled a prestigious Neurodegeneration Research Team comprised of faculty members, researchers, scientists, MBAs and regulatory affairs professionals from all across the USA. The goal of this team is to prepare clinical trial protocols and to create “disease progression models” whereby early detection of all neurodegenerative diseases may be identified, measured and treated.

Dr. Allen Cato of Cato Research Ltd, Durham, North Carolina, is working with this expert team as part of a new approach for the presentation of information to the FDA. The lead scientist of the group is Dr. William S. Lynn also of Cato Research Ltd. Bach Pharma’s coordinator of research is Dr. Joanne M. Ajmo.

Gerard T. Berry, MD
Professor of Pediatrics, Harvard University
Children's Hospital Boston
Genetics/Metabolism
Harvard Medical School
Boston, MA
BACK TO TOP ^

Allen Cato, MD, PhD
Regulatory Affairs Specialist
Cato Research, Ltd., President and CEO
Durham, NC
BACK TO TOP ^

William S. Lynn, MD
Science Advisory Board, Director of Science
Clinical Research Physician
Cato Research Ltd.
Durham, NC
BACK TO TOP ^

Richard J. Miller, PhD, Professor
Northwestern University
Feinberg College of Medicine
Dept. Molecular Pharmacology & Biological Chemistry
Chicago, IL
BACK TO TOP ^

Peter J. Oates, PhD
Oates Biomedical Consulting, LLC
Consultant, Diabetic Complications and Diabetes
Gales Ferry, CT
BACK TO TOP ^

George Stoica, DVM, PhD
Texas A&M University
Department of Pathobiology
College Station, Texas
BACK TO TOP ^

Paul K.Y. Wong, MS, PhD, Professor
The University of Texas
M.D. Anderson Cancer Center
Science Park Research Division
Smithville, TX
BACK TO TOP ^